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Introduction
The Outcome Reduction with an Initial Glargine 
Intervention (ORIGIN) trial is the fourth in a series of 
megatrials that was designed to assess the effect of 
intensive glycaemic control on cardiovascular (CV) 
outcomes in patients with type 2 diabetes. It follows 
the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD),1 Action in Diabetes and Vascular disease: 
preterAx and DiamicroN MR Controlled Evaluation 
(ADVANCE)2 and Veterans Affairs Diabetes Trial (VADT)3 
trials, all of which failed to show any convincing 
evidence for CV disease (CVD) protection with 
intensified glycaemic control.
The ORIGIN study differed from the previous studies in 
that they were designed to assess whether intensified 
glycaemic control could reduce or delay the 
incidence of CV events in patients with longstanding 
(8-10 years) type 2 diabetes and who had previous 
CVD. The ACCORD, ADVANCE and VADT trails have 
been debated extensively in the literature and will not 
be considered further in this review. The difference 
with the ORIGIN study is that while it also recruited 
high-risk individuals, this patient cohort was people 
with impaired fasting glucose (IFG), impaired glucose 
tolerance (IGT) or recently diagnosed diabetes. Thus, 
insulin glargine was administered to a population 
of patients who were not treated with insulin usually. 
Furthermore, intensive glycaemic control was not the 
purpose of the study. The purpose was rather to answer 
the question whether insulin replacement therapy that 
targets fasting normoglycaemia (≤ 5.3 mmol/l) with 
insulin glargine could reduce CV outcomes more than 
standard treatment approaches to dysglycaemia. 
Therefore, the ORIGIN trial was designed primarily 
to explore the effect of insulin therapy with glargine, 
rather than to compare the effect of glucose lowering, 
as studied in other trials.
A second leg of the study explored whether adding 
omega-3 fatty acids would reduce CV death.
This was a multicentre 6.5-year international trial that 
recruited over 12 500 patients. At the 19 sites in South 
Africa, 601 patients were recruited, the fifth highest in 
the world. The trial design, protocol and results were 
presented at the American Diabetes Association 
annual meeting in Philadelphia in June 2012 and have 
been published.4,5 They are available to those who wish 
to study them in detail and will not be reproduced here. 
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Abstract
The results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial were presented at the 
American Diabetes Association meeting in June 2012. The purpose of this study was to assess whether there would 
be any reduction in cardiovascular (CV) events if insulin glargine was started early in the course of diabetes. 
Therefore, the selected patients were those who were at high risk of CV events, but with impaired fasting glucose, 
impaired glucose tolerance or recent onset of type 2 diabetes. After 6.5 years, no differences were seen in primary 
outcomes, namely CV death, myocardial infarction, stroke, revascularisation procedures or hospitalisation for 
heart failure. However, the early institution of insulin therapy using glargine was found to be an effective means of 
maintaining glycaemic control in this patient group. As expected, patients on glargine insulin experienced slightly 
increased rates of both non-severe and severe hypoglycaemia, and slight weight gain. Neither of these problems 
was considered to be a limiting factor in the early use of glargine insulin. A second arm of the study was designed 
to assess the role of omega-3 fatty acids in the prevention of CV events. The results of this arm showed no benefit 
and do not support the use of omega-3 fatty acids as prophylactic therapy in these patients. While the ORIGIN 
trial is unlikely to alter clinical practice regarding the treatment of either dysglycaemia or new-onset diabetes, it 
has demonstrated that glargine insulin is relatively safe when used early in diabetes and can maintain near-normal 
glycaemic control for over six years, without increased cancer risk and with a neutral effect on CV outcomes.
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The effect of glargine insulin on cardiovascular 
outcomes
In terms of primary outcomes, specified as CV death, 
myocardial infarction, stroke, revascularisation proce-
dures or hospitalisation for heart failure, no significant 
difference was documented between those receiving 
glargine insulin vs. those on standard care (Figure 1). 
As might have been expected, symptomatic hypogly-
caemia occurred more commonly in patients in the 
glargine arm of the study. Non-severe hypoglycaemia 
was reported in 17/100 patient years vs. 5/100 patient 
years in subjects on standard therapy, while severe hy-
poglycaemia occurred in 1/100 patient years for those 
on glargine vs. 0.3/100 patient years in patients on stan-
dard therapy. While the difference was statistically sig-
nificant, in clinical terms, it is suggested that the occur-
rence of hypoglycaemia was not a limiting factor in the 
use of glargine insulin. However, there was a threefold 
increase in both severe and non-severe hypoglycae-
mia in patients in the glargine arm of the study, and 
for every 25 patients treated with glargine, there was 
one severe episode of hypoglycaemia. This needs to 
be taken into account when considering if there are 
any possible advantages of initiating early insulin thera-
py with glargine. Patients on glargine also showed a 
mean weight gain of 1.6 kg, compared to a weight loss 
of 0.5 kg in subjects on standard treatment, but again 
a weight differential of 2.1 kg over the duration of the 
study, while statistically significant, is probably not of 
major clinical concern. 
The inability in the glargine arm to reduce the incidence 
of CV events over the 6.5-year duration of the study 
was not unexpected. Notwithstanding the fact that 
these were people with new-onset diabetes, or even 
those with dysglycaemia only, the presence of pre-
existing vascular disease was mandatory for inclusion 
in this study. This created the same problem of trying to 
reverse established vascular disease in only 6.5 years, as 
was seen in the ADVANCE, ACCORD and VADT studies. 
Even in the United Kingdom Prospective Diabetes Study 
(UKPDS),6 which recruited newly diagnosed patients 
without demonstrable vascular disease, it took 20 
years to manifest a significant reduction in myocardial 
infarction rates. 
The ORIGIN study also fell into the trap of the Diabetes 
Mellitus Insulin-Glucose Infusion in Acute Myocardial 
Infarction 2 (DIGAMI 2)7 study. The Diabetes and Insulin-
Glucose Infusion in Acute Myocardial Infarction 1 
(DIGAMI 1)8 study showed that patients treated with 
intensive insulin therapy after a myocardial infarction 
had better outcomes than those whose treatment 
reverted to that of standard care. Following this, many 
units switched all post-myocardial infarction patients to 
insulin as a matter of course. 
The follow-on study (DIGAMI 2) was a larger and longer 
trial, to prove the point that long-term insulin was 
beneficial post-infarction. By the time DIGAMI 2 was 
conceived, most units were treating post-infarction 
patients “intensively”, so it was very difficult to find a 
“standard care” group. Furthermore, overall risk factor 
control had improved. As a result, there was little 
difference between the haemogloblin A1c (HbA1c) 
levels in the standard vs. those in the intensive group 
in DIGAMI 2. There was also no difference in outcome 
post-infarction, whether the patients were treated with 
intensive insulin or so-called “standard care” with oral 
agents. 
In the ORIGIN study, the differences in HbA1c between 
the standard and the glargine groups were minimal 
(Figure 2), so that any effect on the incidence of CVD 
would have been entirely due to the glargine. The 
conclusion that was drawn by the authors of DIGAMI 
2, probably quite correctly, was that good control 
mattered, but it was irrelevant how it was achieved. 
This probably applies equally to the ORIGIN trial, which 
will now be extended as an observational follow-up for 
several more years and will be called the ORIGIN And 
Legacy Effects (ORIGINALE) trial. What the ORIGIN Trial 
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Figure 1: Differences in primary outcomes between the standard 
and the glargine groups




























Figure 2: Differences in haemoglobin A1c between the standard 
and the glargine groups
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safe to use, either as first-line therapy, or early in the 
therapeutic algorithm. It also ended the debate on 
glargine and cancer by showing no difference in 
cancer rates between the two groups, although the 
short-term nature of the trial (only 6.5 years) needs to 
be taken into account when drawing that conclusion. 
This trial also demonstrated that it was both possible 
and safe to reduce the HbA1c to below 6.5% in high-
risk patients without increasing either CV events or the 
mortality rate.
The effect of early glargine therapy in patients 
with dysglycaemia
Recently, there has been interest in the use of insulin 
in early type 2 diabetes and the potential that this 
might have in preserving beta-cell function. Several 
papers9,10 have demonstrated that if used early, insulin 
may promote a period of type 2 diabetes remission. 
However, until the ORIGIN results were published, 
it was unclear whether or not starting insulin during 
the prediabetic phase of dysglycaemia would be of 
benefit. 
Initially, the ORIGIN trial reported a 28% reduction 
in progression to diabetes in this group of patients. 
However, this was assessed within a month of 
completion of the trial, and when reassessed at 100 
days after the trial was stopped, the number of patients 
in remission was only 20%. Therefore, it is unclear what 
the long-term remission rates might be. This should be 
measured against a 58% reduction in progression to 
diabetes with intensive lifestyle changes in both the 
Diabetes Prevention Program (DPP)11 and the Finnish 
Diabetes Prevention Study,12 and a 31% reduction in 
progression in the metformin arm of the DPP.
The role of omega-3 fatty acids
Previous trials have suggested a possible benefit 
from the use of omega-3 fatty acids as a secondary 
prevention option. The (Gruppo Italiano per lo Studio 
della Sopravvivenza nell’Infarto) GISSI trial showed a 
15% reduction in all-cause mortality in post-myocardial 
infarction patients.13 A recent meta-analysis of 
published data indicated a 9% CV mortality benefit.14 
In contrast to this, the ORIGIN trial showed no benefit 
and does not support the use of omega-3 fatty acids 
as prophylactic therapy in these patients. However, 
the previous trials recruited a slightly different patient 
population, namely those who had had a myocardial 
infarction in the previous three months, or those who 
had had heart failure. In addition, the dose of omega-3 
fatty acids that was given was higher in previous trials. 
Furthermore, participants in ORIGIN were taking more 
concomitant cardioprotective medication than those 
in previous trials. Potentially, this could have reduced 
the incidence of death from CV causes, thereby 
reducing the statistical power to detect any effect of 
the omega-3 fatty acids. 
Conclusion
It is unlikely that the ORIGIN results will alter 
clinical practice regarding the treatment of either 
dysglycaemia or new-onset diabetes. Nevertheless, 
while largely a negative study, there were some positive 
findings. This study has shown that glargine insulin is 
relatively safe when used early in diabetes and can 
maintain near-normal glycaemic control for over six 
years without increased cancer risk and with a neutral 
effect on CV outcomes. There was only a modest 
increase in hypoglycaemia and weight with its use. 
Glargine also slows the progression of dysglycaemia. 
Targeting an HbA1c of 6.5% in this group of high-risk 
patients with vascular disease appears to be a safe 
option. The routine use of omega-3 fatty acids in high-
risk patients is not supported by the outcomes of this 
trial.
Disclosure 
Dr Larry Distiller has consulted and lectured for Sanofi 
South Africa and has been appointed as the national 
ORIGIN trial spokesman for Sanofi South Africa.
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